Dendritic cells in progression and pathology of HIV infection

Trends in Immunology

Volumn 35, Issue 3, 2014, Pages 114-122

  Manches, Olivier ^a   Frleta, Davor ^a,b   Bhardwaj, Nina ^a  

^a MOUNT SINAI HOSPITAL   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Dendritic; HIV; Immune activation; Infection; Pathogenesis

Indexed keywords

DENDRITIC; HIV; IMMUNE ACTIVATION; INFECTION; PATHOGENESIS;

ANTIGEN PRESENTATION; DENDRITIC CELLS; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 84894435407     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.10.003     Document Type: Review

References (125)

1. Miller C.J. Host and viral factors influencing heterosexual HIV transmission. Rev. Reprod. 1998, 3:42-51.
2. Sallusto F., et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 1998, 28:2760-2769.
3. Turville S.G., et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat. Immunol. 2002, 3:975-983.
4. Lambert A.A., et al. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 2008, 112:1299-1307.
5. de Witte L., et al. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19464-19469.
6. Beignon A.S., et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 2005, 115:3265-3275.
7. Schmidt B., et al. HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology 2005, 343:256-266.
8. Sandgren K.J., et al. Human plasmacytoid dendritic cells efficiently capture hiv-1 envelope glycoproteins via CD4 for antigen presentation. J. Immunol. 2013, 191:60-69.
9. Izquierdo-Useros N., et al. Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood 2009, 113:2732-2741.
10. Hatch S.C., et al. Glycosphingolipid composition of human immunodeficiency virus type 1 (HIV-1) particles is a crucial determinant for dendritic cell-mediated HIV-1 trans-infection. J. Virol. 2009, 83:3496-3506.
11. Gummuluru S., et al. Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway. J. Virol. 2003, 77:12865-12874.
12. Hanley T.M., et al. PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection. PLoS Pathog. 2010, 6:e1000981.
13. Izquierdo-Useros N., et al. Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission. J. Virol. 2007, 81:7559-7570.
14. Lepelley A., et al. Innate sensing of HIV-infected cells. PLoS Pathog. 2011, 7:e1001284.
15. Geijtenbeek T.B., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
16. de Witte L., et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat. Med. 2007, 13:367-371.
17. O'Brien M., et al. Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-alpha-producing and partially matured phenotype. J. Clin. Invest. 2011, 121:1088-1101.
18. Li Q., et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009, 458:1034-1038.
19. Fontenot D., et al. TSLP production by epithelial cells exposed to immunodeficiency virus triggers DC-mediated mucosal infection of CD4+ T cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:16776-16781.
20. Zhang Z.Q., et al. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5640-5645.
21. Miller C.J., et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 2005, 79:9217-9227.
22. Cameron P.U., et al. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 1992, 257:383-387.
23. Pope M., et al. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell 1994, 78:389-398.
24. Lore K., et al. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J. Exp. Med. 2005, 201:2023-2033.
25. Weissman D., et al. The efficiency of acute infection of CD4+ T cells is markedly enhanced in the setting of antigen-specific immune activation. J. Exp. Med. 1996, 183:687-692.
26. Douek D.C., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95-98.
27. McDonald D., et al. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003, 300:1295-1297.
28. Boggiano C., et al. Dendritic cell-mediated trans-enhancement of human immunodeficiency virus type 1 infectivity is independent of DC-SIGN. J. Virol. 2007, 81:2519-2523.
29. Smed-Sorensen A., et al. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J. Virol. 2005, 79:8861-8869.
30. Pion M., et al. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J. Exp. Med. 2006, 203:2887-2893.
31. Sheehy A.M., et al. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 2003, 9:1404-1407.
32. Grutter M.G., Luban J. TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling. Curr. Opin. Virol. 2012, 2:142-150.
33. Battivelli E., et al. Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms. J. Virol. 2011, 85:7828-7835.
34. Coleman C.M., et al. Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. Retrovirology 2011, 8:26.
35. Hrecka K., et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474:658-661.
36. Laguette N., et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474:654-657.
37. Goldstone D.C., et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011, 480:379-382.
38. Lahouassa H., et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 2012, 13:223-228.
39. White T.E., et al. The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe 2013, 13:441-451.
40. Bloch N., et al. HIV-1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 that cannot be counteracted by Vpx. AIDS Res. Hum. Retroviruses 2013, 10.1089/aid.2013.0119.
41. Meylan P.R., et al. Mechanisms for the inhibition of HIV replication by interferons-alpha, -beta, and -gamma in primary human macrophages. Virology 1993, 193:138-148.
42. Goujon C., et al. Evidence for IFNalpha-induced, SAMHD1-independent inhibitors of early HIV-1 infection. Retrovirology 2013, 10:23.
43. Goujon C., et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013, 10.1038/nature12542.
44. Gringhuis S.I., et al. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat. Immunol. 2010, 11:419-426.
45. Iwasaki A. Innate immune recognition of HIV-1. Immunity 2012, 37:389-398.
46. Stetson D.B., et al. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598.
47. Yan N., et al. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 2010, 11:1005-1013.
48. Goujon C., et al. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther. 2006, 13:991-994.
49. Manel N., et al. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010, 467:214-217.
50. Gao D., et al. Cyclic GMP-AMP synthase is an innate immune sensor of hiv and other retroviruses. Science 2013, 341:903-906.
51. Honda K., et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005, 434:1035-1040.
52. Sasai M., et al. Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 2010, 329:1530-1534.
53. Van Kooyk Y., Geijtenbeek T.B. DC-SIGN: escape mechanism for pathogens. Nat. Rev. Immunol. 2003, 3:697-709.
54. Blanchet F.P., et al. Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses. Immunity 2010, 32:654-669.
55. Meyer-Wentrup F., et al. DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. J. Leukoc. Biol. 2009, 85:518-525.
56. Kerkmann M., et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 2003, 170:4465-4474.
57. Lee H.K., et al. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 2007, 315:1398-1401.
58. Henault J., et al. Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. Immunity 2012, 37:986-997.
59. Sabado R.L., et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood 2010, 116:3839-3852.
60. Donaghy H., et al. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 2003, 101:4505-4511.
61. Kodama A., et al. Impairment of in vitro generation of monocyte-derived human dendritic cells by inactivated human immunodeficiency virus-1: Involvement of type I interferon produced from plasmacytoid dendritc cells. Hum. Immunol. 2010, 71:541-550.
62. Swiecki M., et al. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J. Exp. Med. 2011, 208:2367-2374.
63. Dillon S.M., et al. Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J. Acquir. Immune Defic. Syndr. 2008, 48:1-12.
64. Lehmann C., et al. Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients. PLoS ONE 2010, 5:e11110.
65. Nascimbeni M., et al. Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression. Blood 2009, 113:6112-6119.
66. Fonteneau J.F., et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J. Virol. 2004, 78:5223-5232.
67. Wonderlich E.R., et al. Dissecting the role of dendritic cells in simian immunodeficiency virus infection and AIDS. Immunol. Res. 2011, 50:228-234.
68. Brown K.N., et al. Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathog. 2009, 5:e1000413.
69. Wijewardana V., et al. Early myeloid dendritic cell dysregulation is predictive of disease progression in simian immunodeficiency virus infection. PLoS Pathog. 2010, 6:e1001235.
70. Macatonia S.E., et al. Suppression of immune responses by dendritic cells infected with HIV. Immunology 1989, 67:285-289.
71. Roberts M., et al. Dendritic cells from HIV-1 infected individuals show reduced capacity to stimulate autologous T-cell proliferation. Immunol. Lett. 1994, 43:39-43.
72. Martinson J.A., et al. Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell. Immunol. 2007, 250:75-84.
73. McMichael A.J., et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 2010, 10:11-23.
74. Doitsh G., et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010, 143:789-801.
75. Cooper A., et al. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 2013, 498:376-379.
76. Finkel T.H., et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat. Med. 1995, 1:129-134.
77. Frleta D., et al. HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J. Clin. Invest. 2012, 122:4685-4697.
78. Miller E.A., et al. Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway. J. Acquir. Immune Defic. Syndr. 2012, 61:535-544.
79. Sabado R.L., et al. Pathways utilized by dendritic cells for binding, uptake, processing and presentation of antigens derived from HIV-1. Eur. J. Immunol. 2007, 37:1752-1763.
80. Moris A., et al. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 2004, 103:2648-2654.
81. Van Montfort T., et al. HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. J. Immunol. 2011, 187:4676-4685.
82. Buseyne F., et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat. Med. 2001, 7:344-349.
83. Hoeffel G., et al. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 2007, 27:481-492.
84. Poulin L.F., et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J. Exp. Med. 2010, 207:1261-1271.
85. Radford K.J., Caminschi I. New generation of dendritic cell vaccines. Hum. Vaccines Immunother. 2013, 9:259-264.
86. Ng C.T., et al. Networking at the level of host immunity: immune cell interactions during persistent viral infections. Cell Host Microbe 2013, 13:652-664.
87. Brehm M.A., et al. Humanized mice for the study of infectious diseases. Curr. Opin. Immunol. 2013, 25:428-435.
88. Hazenberg M.D., et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003, 17:1881-1888.
89. Baker J.V., Duprez D. Biomarkers and HIV-associated cardiovascular disease. Curr. Opin. HIV AIDS 2010, 5:511-516.
90. Klatt N.R., et al. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013, 21:6-13.
91. Klatt N.R., et al. Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol. 2012, 5:646-657.
92. Kwa S., et al. Plasmacytoid dendritic cells are recruited to the colorectum and contribute to immune activation during pathogenic SIV infection in rhesus macaques. Blood 2011, 118:2763-2773.
93. Reeves R.K., et al. SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa. J. Infect. Dis. 2012, 206:1462-1468.
94. von Sydow M., et al. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res. Hum. Retroviruses 1991, 7:375-380.
95. Herbeuval J.P., et al. Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:7000-7005.
96. Bosinger S.E., et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J. Clin. Invest. 2009, 119:3556-3572.
97. Jacquelin B., et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J. Clin. Invest. 2009, 119:3544-3555.
98. Herbeuval J.P., et al. CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood 2005, 106:3524-3531.
99. Demoulins T., et al. Reversible blockade of thymic output: an inherent part of TLR ligand-mediated immune response. J. Immunol. 2008, 181:6757-6769.
100. Tough D.F., et al. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996, 272:1947-1950.
101. Reed J.R., et al. Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J. Exp. Med. 2004, 199:1433-1443.
102. Sedaghat A.R., et al. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J. Virol. 2008, 82:1870-1883.
103. Wilson E.B., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
104. Teijaro J.R., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
105. Kulpa D.A., et al. The immunological synapse: the gateway to the HIV reservoir. Immunol. Rev. 2013, 254:305-325.
106. Handley S.A., et al. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 2012, 151:253-266.
107. Moeller A.H., et al. SIV-induced instability of the chimpanzee gut microbiome. Cell Host Microbe 2013, 14:340-345.
108. Kader M., et al. Blocking TLR7- and TLR9-mediated IFN-alpha production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection. PLoS Pathog. 2013, 9:e1003530.
109. Favre D., et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009, 5:e1000295.
110. Boasso A., et al. Do regulatory T-cells play a role in AIDS pathogenesis?. AIDS Rev. 2006, 8:141-147.
111. Guo B., et al. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 2008, 118:1680-1690.
112. Munn D.H., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005, 22:633-642.
113. Favre D., et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2010, 2:32ra36.
114. Malleret B., et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 2008, 112:4598-4608.
115. Manches O., et al. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J. Clin. Invest. 2008, 118:3431-3439.
116. Manches O., et al. Activation of the noncanonical NF-kappaB pathway by HIV controls a dendritic cell immunoregulatory phenotype. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:14122-14127.
117. Baban B., et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 2009, 183:2475-2483.
118. Sharma M.D., et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009, 113:6102-6111.
119. Takagi H., et al. Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity in vivo. Immunity 2011, 35:958-971.
120. d'Ettorre G., et al. HIV-associated immune activation: from bench to bedside. AIDS Res. Hum. Retroviruses 2011, 27:355-364.
121. Ting P.T., Koo J.Y. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int. J. Dermatol. 2006, 45:689-692.
122. Garcia F., et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci. Transl. Med. 2013, 5:166ra162.
123. Barber D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
124. Dyavar Shetty R., et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J. Clin. Invest. 2012, 122:1712-1716.
125. Ivanov I.I., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.